A highly complex pattern of loss of constitutional heterozygosity (LOH) is observed in human malignancy. Most current models of carcinogenesis assume clonal development of the tumour, with successive genetic lesions conferring an increased proliferative advantage. At the simplest level therefore, every LOH event observed should reflect some such advantage to the malignant cell. However, the situation is likely to be more complicated. If two lesions occur within the same cell at the same time, one conferring a growth advantage the other being silent, then selective pressure will favour the first but both will be present in the resulting clone. This situation may result in confusion over which genomic alterations, in any given tumour, have contributed to the malignant phenotype. It is assumed that if an LOH event occurs at high frequency (>20% of tumours of a particular type) then it is likely to reflect loss of wild-type function of a tumour-suppressor gene encoded within the region of loss.
An individual with a germline mutation in a tumoursuppressor gene might display an increased risk of malignant disease. The individual may pass on this mutation to children who will incur a similar disease risk. Analysis of subsequent tumours often shows that the corresponding normal allele has been deleted in an LOH event. In the case of familial disease, where a genetic linkage or cytogenetic abnormality has helped to target the disease locus, a number of novel tumour-suppressor genes have been identified, including WTJ (Call et al., 1990) , RBI (Weinberg, 1990) , BRCAJ (Miki et al., 1994) and APC (Joslyn et al., 1991) . Conversely, LOH analysis alone has been a historically less successful route to suppressor identification. However, given the imminent localisation of the majority of human genes, the best application of such work might be to provide evidence for the involvement of particular regions in the development of disease. Genes sublocalised to these areas can be quickly examined for a role in malignancy.
Loss of function of the p53 protein, located within 17pl3.1, is an important event in the initiation/progression of many human tumours (Baker et al., 1989; Prosser et al., 1990; Mitsudomi et al., 1992) . However, LOH studies in breast cancer have suggested the presence of another tumoursuppressor gene mapped to chromosomal region 17pl3.3 (Coles et al., 1990; Cornelis et al., 1994; Merlo et al., 1994) . Our recent work revealed a complex pattern of LOH in this region in breast tumours (Stack et al., 1995) . The highest loss (60-70%), and therefore perhaps the most likely site of the putative suppressor gene, was defined by the three most distal 17p markers, D17S926, D17S695 and D17S849, which were mapped and ordered by fluorescence in situ hybridisation (FISH) to a position near the telomere (for physical map of markers, see Stack et al., 1995) . Although some tumours showed loss across the whole region studied, many showed retention of more proximal markers, excluding a direct involvement of TP53. However, in order to define the extent of the deletions observed and to investigate involvement of the telomere, more distal markers were required. Yeast artificial chromosomes (YACs), encoding inserts derived from a number of human telomeres, including 17p, were isolated by constructing and screening a single arm, vector library with a TTAGGG 40mer probe (Vocero Akbani et al., 1996) . Encoded microsatellite repeat markers were subsequently identified from many telomeres. However, none were isolated from the 17p-encoding YAC. An alternative strategy was therefore employed and the restriction fragment length polymorphism (RFLP) systems derived were used to investigate LOH in several tumour types.
Materials and methods
Patient information and DNA extraction Paired primary breast tumours and normal samples were obtained from patients at the S. Giovanni Vecchio Hospital, Turin, Italy as previously outlined (Merlo et al., 1994 2p (sFJS14) 6q (sAVA3) Ilp (D1lS2071) 14q (D14S826) 16q (D16S303) 18q ( Other microsatellites Details of other primer sequences previously reported are: D17S925, D17S926, D17S849 (Gyapay et al., 1994) ; D17S625 (Utah 269) (Gerken et al., 1995); cCII7.713 (Stack et al., 1994) ; TP53 (Jones and Nakamura, 1992) ; cCI17-571, D17S1147 (Stack et al., 1995 A similar LOH study was conducted using resectable staged, non-small-cell lung tumours, the results of which are shown in Table III 
Discussion
We have previously reported evidence for the existence of a breast cancer-suppressor gene located within the distal region of 17pl3.3. This study, reporting the identification of a novel four-allele RFLP system mapped to the 17p subtelomeric region, extends those initial observations. In almost all cases examined, the loss region incorporating the distal markers extends to the telomere. Could we therefore be justified in ascribing the LOH events observed to simple loss of subtelomeric sequences in an unstable genome? This explanation would seem unlikely, given that the levels of loss at the distal regions of other chromosomes occurred at a substantially lower frequency. We would therefore argue that the breast tumour data presented in this study support the hypothesis that a p53-independent suppressor gene resides within the subtelomeric region of 17pl3.3.
Although both breast and lung cancers are epithelial in origin and have known p53 involvement (Prosser et al., 1990; Mitsudomi et al., 1992) , there is a marked difference between (Foulkes et al., 1993) . The LOH pattern for breast cancers was much more complex, with individual samples showing both loss and no loss for different markers along the 17p arm. It is interesting to speculate on the observation that the region of loss on 17p for lung tumours is so large, possibly including the entire 17p arm. It is possible that TP53 (or another suppressor) is the sole target of the LOH events. In this case the large region of loss could be a result of the particular carcinogenic agents that lung tissue is exposed to. Alternatively, defects within two or more separate and distant genes situated on 17p may be required for tumorigenesis. Possible support for the existence of multiple 17p suppressor targets is provided by the observation of LOH at the TP53 locus in lung tumours in the absence of a detectable mutation in the remaining allele (Hiyama et al., 1995) .
To our knowledge, this is the first major study of the loss of telomere-associated sequences in malignant disease. The levels of loss found, in both lung and breast cancer, for the majority of telomeric markers was, in the main, similar to the levels considered to be around the borderline for significant involvement of a region in the development of a tumour type (10-20%). We are therefore unable to support the idea that subtelomeric sequences are highly unstable in malignant disease. Given that telomeres are thought to be required for chromosome stability, the high level of loss of 17TEL observed might appear surprising. However, if the loss mechanism was primarily one of somatic recombination and reduplication following the LOH event, both 17 homologues would have functional telomeres. Alternatively, if the LOH events derived from breakage and loss of the chromosome end, it is possible that telomerase, activated in the malignant cells, might be involved in re-creation of a functional telomere at the break site. Telomere capture (Meltzer et al., 1993 ) is a further mechanism by which a chromosome might reacquire a functional terminus. The primary aim of this work was to provide evidence for the existence of and fine location of, a 17pl 3.3-encoded suppressor gene. Although the region showed very high levels of loss in lung cancer, strongly supporting the existence of a 17p tumour suppressor, the homogeneity of the deletions and size of the region involved meant that almost no fine positional information was derived. In contrast, while still showing high LOH levels for distal markers, many breast tumours showed a more heterogeneous 17pl3.3 loss pattern, from which it might be possible to derive positional information. However, we are faced with a problem. If 
